• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Director Disbrow Joshua R. was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

    5/16/25 6:00:09 PM ET
    $ZYXI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ZYXI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Disbrow Joshua R.

    (Last) (First) (Middle)
    9655 MAROON CIRCLE

    (Street)
    ENGLEWOOD CO 80112

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ZYNEX INC [ ZYXI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/15/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock (Restricted Stock Award) 05/15/2025 A 10,000(1) A $0 22,500(2) D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents a restricted stock award issued pursuant to the Issuer's 2017 Stock Incentive Plan (the "Plan") pursuant to which the 10,000 shares vest equally, on a quarterly basis, over a period of three years beginning one quarter from the grant date.
    2. Represents restricted stock awards under the Plan, which have not vested.
    /s/ Joshua R. Disbrow 05/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ZYXI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYXI

    DatePrice TargetRatingAnalyst
    3/12/2025$11.00 → $5.50Outperform → Sector Perform
    RBC Capital Mkts
    3/12/2025Buy → Neutral
    Ladenburg Thalmann
    10/16/2023$13.00Outperform
    RBC Capital Mkts
    1/6/2023$10.00 → $18.00Neutral → Overweight
    Piper Sandler
    2/28/2022$15.50 → $10.00Buy
    B. Riley Securities
    2/25/2022$22.00 → $20.00Buy
    HC Wainwright & Co.
    7/30/2021$25.00 → $22.00Buy
    HC Wainwright & Co.
    7/16/2021$19.50Neutral → Buy
    B. Riley Securities
    More analyst ratings

    $ZYXI
    SEC Filings

    See more
    • Zynex Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - ZYNEX INC (0000846475) (Filer)

      5/15/25 5:11:13 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ZYNEX INC (0000846475) (Filer)

      5/14/25 5:04:50 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by Zynex Inc.

      10-Q - ZYNEX INC (0000846475) (Filer)

      4/29/25 5:00:23 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Leadership Updates

    Live Leadership Updates

    See more
    • Zynex Announces Open Oximetry Project Membership

      ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member. The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to i

      12/3/24 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Announces Change of Auditor

      ENGLEWOOD, Colo., June 13, 2022 /PRNewswire/ -- Zynex, Inc. ("Zynex or the "Company) (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has changed its auditors from Plante & Moran, PLLC ("Plante Moran") as the Company's independent registered accounting firm to Marcum LLP effective June 13, 2022. The appointment of Marcum LLP was made after careful consideration and an evaluation process by the Company and approved by the Board of Directors and the Audit Committee of the Company.

      6/13/22 4:30:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Appoints Donald Gregg as Vice President of Sales and Operations of Monitoring Solutions Division

      ENGLEWOOD, Colo., April 20, 2021 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics today announced that it has hired Donald Gregg as the Vice President of Sales and Operations of its Monitoring Solutions Division. In this position, Donald will lead operations, sales, marketing and product development of the Monitoring Solution Division including the production and launch of the CM-1500 Blood Volume Monitor which was granted 510(k) clearance by the U.S. Food and Drug Administration in 2020.

      4/20/21 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Zynex Submits FDA Application for Its NiCO Laser Pulse Oximeter

      ENGLEWOOD, Colo., May 12, 2025 /PRNewswire/ --  Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has submitted a 510(k) application to the U.S. Food and Drug Administration ("FDA") for its NiCO™, Noninvasive CO-Oximeter device. This submission marks a historic milestone in the evolution of pulse oximetry and a major breakthrough for the Company in its mission to improve the quality of care and patient outco

      5/12/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Reports First Quarter 2025 Financial Results

      ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary  "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap

      4/29/25 4:02:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Sets First Quarter 2025 Earnings Call

      ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

      4/22/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Disbrow Joshua R. was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:09 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Cress Michael D was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:05 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Michaels Barry D was granted 10,000 shares, increasing direct ownership by 80% to 22,500 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      5/16/25 6:00:08 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $ZYXI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Disbrow Joshua R. bought $58,233 worth of shares (7,000 units at $8.32), increasing direct ownership by 11% to 72,000 units (SEC Form 4)

      4 - ZYNEX INC (0000846475) (Issuer)

      7/30/24 6:25:26 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex downgraded by RBC Capital Mkts with a new price target

      RBC Capital Mkts downgraded Zynex from Outperform to Sector Perform and set a new price target of $5.50 from $11.00 previously

      3/12/25 7:36:55 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex downgraded by Ladenburg Thalmann

      Ladenburg Thalmann downgraded Zynex from Buy to Neutral

      3/12/25 7:36:29 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • RBC Capital Mkts initiated coverage on Zynex with a new price target

      RBC Capital Mkts initiated coverage of Zynex with a rating of Outperform and set a new price target of $13.00

      10/16/23 7:17:56 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Financials

    Live finance-specific insights

    See more
    • Zynex Reports First Quarter 2025 Financial Results

      ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025. Management Commentary  "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was ap

      4/29/25 4:02:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Sets First Quarter 2025 Earnings Call

      ENGLEWOOD, Colo., April 22, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, will hold a conference call on Tuesday, April 29, 2025 at 4:15 PM Eastern Time to discuss its financial results for the first quarter ended March 31, 2025.  Financial results will be issued in a press release prior to the call. Zynex management will host the conference call, followed by a question and answer session. Date: Tuesday

      4/22/25 9:15:00 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Zynex Reports Fourth Quarter and Full Year 2024 Financial Results

      ENGLEWOOD, Colo., March 11, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ:ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the fourth quarter and full year ended December 31, 2024. Key Highlights and Business Update FY 2024 orders increased 16% year-over-yearFY 2024 net revenue increased 4% to $192.4 millionFY 2024 net income of $3.0 million; Diluted EPS $0.09FY 2024 cash flow from operations of

      3/11/25 4:08:00 PM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ZYXI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Zynex Inc. (Amendment)

      SC 13D/A - ZYNEX INC (0000846475) (Subject)

      5/24/23 6:26:30 AM ET
      $ZYXI
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care